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Background
Hypoiia, a frequent effect of solid tumor growth, seles to generate a cascade of molecuiar pathways
which include angiogenesis, glycolysis and various cell-cycle control proteins.[l] Hypoxia creates
conditions that, on one hand, are conducive to the accumulation of extracellular adenosine and, on the
other, stabilize hypoxia-inducible factors, such as HIF-1u.[2]
Aims
The aim of this study was to use combined homology modeling, molecular dynamics, 3D-QSAR, and
molecular docking studies to identifi leads with inhibitory activity towards HIF-1o and A3 adenosine
receptors. Their functions can be specifically inhibited by:
l) blocking protein-protein interaction between C-terminal transactivation domain (CTAD) of HIF-1o
and p300;
2) hypoxia response lements (HRE) at the DNA consensus sequence binders;
3) A3 receptor antagonists.
Methods
HIF-1o homology model was built with I-TASSER based on multiple-threading alignments
(LoMETs/iterative TASSER assembly simulations). To screen within ZINC-DB small molecules, that
might be inhibitors, HIF-Ic/HRE complex and NMR structure of HIF-lo/p300 were used in docking
procedure. The identified molecules were redocked into target using InducedFit.l3] Dynamic simulation
of the complex was performed by DESMOND.[3] Homology model of the ,A.3 receptor was constructed.
Phospholipid bilayer was built around the receptor, and molecular dynamic simulations were carried out
with DESMOND. Pharmacophore model, developed by PHASE,[3] was used to search 3D-databases to
identifi additional molecules possessing a higher affinity.
Results
Since a X-ray HIF-1o crystal structure was not reported yet, a homology model using multiple templates
was built (Fig. l). Quality of the obtained model was higher in the PAS regions of the HIF protein, which
has highly conserved amino acid sequence and structue. Ramachandran plot analysis showed tha|87.7 %
of residues were in allowed region. HIF-1o/p300 complex (PDB code:lL3E) was used in ZINC database
to search novel potential inhibitors. Identified inhibitors were docked into the protein target- To keep the
receptor flexible during the docking procedure, Induced Fit Docking (IFD) protocol was used Key
interactions between protein and ligands were further arnlyzed. Ligands establish hydrogen bonding
interactions with Asp331, Ser395, Gln398, Gln342, and His402. IFD model confirms the observations
emersed from flexible dockins. Low RMSD values and similar interactions were observed
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Furthermore, molecular docking studies on the HRE fragment (PDB code: IDTG) were performed, using
a large library of compounds selected from NCI database with the virtual screening workflow of GLIDE.
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The best docked compounds obtained are all heterocyclic molecules, anthracycline analogues with
peptide linkers of different lengths. Thus, they can intercalate between the DNA stacking bases (Fig. 2).
Fig.2
The recently published structures of hA2AR provide a new template for A3R modeling. A new model of
the hA3R was built using this crystal structure as template (Fig. 3). The validation of the obtained
structure model was performed by inspecting the Ramachandran plot. Molecular dynamics, in a
phospholipid bilayer, was be used to understand the plausible binding modes and interactions of A3R. A
training data set of 122 A3R active and selective antagonists were docked into the obtained model using
IFD. Then, pharmacophore models based on common chemical features of molecule with inhibitory
activity towards A3R were generated with PHASE. The resulting pharmacophore model contained an
aromatic ring, a hydrogen-bond donor, and three hydrophobic sites. To each pharmacophore feature site
was first assigned an energetic value equal to the sum of the GLIDE XP conhibutions of the atoms
included in the site. This procedure allows sites to be quantified and ranked on the basis of these energetic
terms. Ushg these pharmacophore features, a large public library of compounds (ZINC lead-like) was
screened, to identify new hits that could inhibit the A3 receptor.
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Conclusion
The role ofhypoxia in cancer cells was analyzed, in particular its ability to regulate the expression of
Hypoxia-Inducible Factor-lo through the ,{3 receptor inhibition. It is recognized that the inhibition of
HIF-1o activity represents novel therapeutic approach to cancer therapy. Due to the ability of 43
adenosine receptor antagonists to block HIF-1a protein expression accumulation in hypoxia, selective
inhibitors of HIF-1g and A3R were identified and proposed for use in cancer therapy.
References
1'Semenza, G.L.; Wang, G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human
erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol.1992, 12,5447-5454.
2.Merighi, s.; Benini, A.; Mirandola, P.; Gessi, s.; Varani, K.; Leung, E.; Maclennan, S.; Borea, p.A. A3 adenosine
receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase (Pl3KyAKT-dependent inhibition of
the extracellular signal-regulated kinase (ERK)1/2 phosphorylation in 4,375 human melanoma cells. J. Biol. Chem.
2005, 280, t9 5 t6-19526.
3.Maestro, version 8.5, Schr6dinger, LLC, New York, Ny,2008.
M L. i ;e4 l i , l#
t t 2
